全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2015 

利用患者骨髓瘤细胞建立NOD/SCID小鼠多发性骨髓瘤模型
Establishment of NOD/SCID-mouse model with multiple myeloma using myeloma cells from patients

DOI: 10.7652/jdyxb201504011

Keywords: 多发性骨髓瘤,NOD/SCID小鼠,模型
multiple myeloma
,NOD/SCID-mouse,model

Full-Text   Cite this paper   Add to My Lib

Abstract:

摘要:目的 探讨利用多发性骨髓瘤患者骨髓瘤细胞经植入兔骨建立NOD/SCID小鼠多发性骨髓瘤模型的可行性。方法 分离取出新西兰白兔股骨与胫骨,清除肌肉、骨膜及软骨组织,沿中间轻柔截断;准备4~6周体质量约25~30g的NOD/SCID小鼠,腹腔注射麻醉,将兔骨植入小鼠后背部,4周后检测兔骨植入成活情况。将分选的多发性骨髓瘤患者CD38+/CD45-的浆细胞5×106经过免疫荧光标记后,由远侧端缓缓注入植入兔骨内。每周观察成瘤情况,采用living-Imaging方法检测小鼠体内浆细胞的生长情况,病理检测肿块性质。 结果 兔骨植入后4周成活,将分选的多发性骨髓瘤患者骨髓瘤细胞注入兔骨后,2周可见NOD/SCID小鼠荷瘤,8周后肿瘤体积大小约100mm3。living-Imaging方法检测结果显示,在注射后2周可见兔骨局部有浆细胞浓聚,随着注射时间的延长,至注射后8周局部浆细胞浓聚现象更加明显(2.4×104 vs. 1.5×105,P<0.05)。肿块病理活检可见大量浆细胞浸润,植入兔骨结构破坏,破骨细胞增多。结论 NOD/SCID小鼠兔骨植入可有效支持多发性骨髓瘤患者浆细胞局部注射,并建立NOD/SCID小鼠骨髓瘤模型,为骨髓瘤相关体内实验及临床药物筛选提供实验模型。
ABSTRACT: Objective To explore the feasibility of establishment of NOD/SCID-mouse model with multiple myeloma by using plasma cells from myeloma patients. Methods The femurs and tibias were removed from the New Zealand white rabbits; the muscles, periosteum and cartilage tissues were cleared. Then each bone was cut into two pieces gently along its middle. The NOD/SCID mice weighing 25-30g (4-6 weeks) were anesthetized by intraperitoneal injection; rabbit bone was inserted into the right side of the mouse back and engraftment of the bones was allowed to take place after 4 weeks. The 5000 000 purified plasma cells which expressed CD38+/CD45- were immunofluorescence labeled and then injected slowly into the implanted rabbit bone through the distal end. The mice were observed weekly; the plasma cells growth in mice was screened by the living-imaging system and the tumor from the mice was determined by biopsy. Results The implanted rabbit bone survived after 4 weeks. The tumor in mice was observed 2 weeks after the purified myeloma cells were injected into the rabbit bone, and it reached 100mm3 after 8 weeks. Results of the living-imaging system showed that the myeloma cells had uptake in the rabbit bone after 2 weeks of injection and this phenomenon was more pronounced after 8 weeks of injection (2.4×104 vs. 1.5×105, P<0.05). The tumor infiltrated with numerous plasma cells and osteoclasts increased upon the biopsy. Conclusion Rabbit bone marrow implanted into NOD/SCID mice can effectively support local injection of plasma cells of multiple myeloma patients, and the NOD/SCID-mouse model of myeloma has been established. This model can be used to study in vivo experiments related to myeloma and clinical therapeutic approaches for this disease

References

[1]  刘芹芹,刘佳丽,郭冬梅,等. γ-分泌酶抑制剂对人多发性骨髓瘤细胞系RPMI-8226细胞小鼠移植瘤的抑制作用[J]. 中华血液学杂志, 2013, 34(9):794-797.
[2]  CROUCHER PI, SHIPMAN CM, LIPPITT J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma[J]. Blood, 2001, 98(13):3534- 3540.
[3]  JO?GO C, COELHO I, COSTA C, et al. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma-Real life experience of a tertiary cancer center[J]. Ann Hematol, 2015, 94:97-105.
[4]  URASHIMA M, CHEN BP, CHEN S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow[J]. Blood, 1997, 90(2):754-765.
[5]  YACCOBY S, BARLOGIE B, EPSTEIN J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations[J]. Blood, 1998, 92(8):2908-2913.
[6]  YATA K, YACCOBY S. The SCID-rab model: a novel <strong>in vivo</strong> system for primary human myeloma demonstrating growth of CD138-expressing malignant cells[J]. Leukemia, 2004, 18(11):1891-1897.
[7]  李琰,杜恒飞,方洁,等. 去甲斑蝥素抗多发性骨髓瘤效应的体内实验研究[J]. 中华血液学杂志, 2013, 34(11):970-973.
[8]  VANDERKERKEN K, DE LEENHEER E, SHIPMAN C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma[J]. Cancer Res, 2003, 63(2):287-289.
[9]  VAN VALCKENBORGH E, DE RAEVE H, DEVY L, et al. Murine 5T multiple myeloma cells induce angiogenesis <strong>in vitro</strong> and <strong>in vivo</strong>[J]. Br J Cancer, 2002, 86(5):796-802.
[10]  BIRD JM, OWEN RG, D??SA S, et al. Guidelines for the diagnosis and management of multiple myeloma[J]. Br J Haematol, 2011, 154(1):32-75.
[11]  MOREAU P, RICHARDSON PG, CAVO M, et al. Harousseau, Proteasome inhibitors in multiple myeloma: 10 years later[J]. Blood, 2012, 120(5):947-959.
[12]  ANDERSON KC, ALSINA M, BENSINGER W, et al. Multiple myeloma, version 1. 2013[J]. J Natl Compr Canc Netw, 2013, 11(1):11-18.
[13]  ZHU J, WANG M, CAO B, et al. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma[J]. Curr Med Chem, 2014, 21(27):3173-3187.
[14]  DE LA PUENTE P, MUZ B, AZAB F, et al. Molecularly targeted therapies in multiple myeloma[J]. Leuk Res Treatment, 2014, 16.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133